Skip to main content
OpenTrials
Completed

NCT Number: NCT02553512

Helius in Hypertension-I: The UK Hypertension Registry

The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

In patients with persistent essential systolic hypertension,who are undergoing assessment of their current pharmaceutical burden for blood pressure control, a digital health offering is used (1) to provide automatic and passive electronic documentation of medication adherence and patterns of medication taking, (2) to assist providers in distinguishing inadequate medication adherence or pharmacologic unresponsiveness as the root cause for persistent hypertension, and (3) to inform management decisions (dose adjustment, medication addition or substitution, adherence counseling, referral to a hypertension specialist).

Participating patients wear an adhesive Wearable Sensor ("Patch") continuously with replacement after one week, and ingest an inert tablet ("Pill") containing an Ingestible Sensor daily whenever they take their prescribed anti-hypertensive drugs.

The Patch automatically detects and records the dates and times of each "Pill" ingestion, daily step count, sleep duration and sleep interruptions, and the circadian pattern of rest and activity. After completion of each Patch's use, the recorded data are downloaded and incorporated into a report that includes blood pressures that are obtained at the time of clinic visits at the beginning and after 2 weeks of service use.

The final report is generated automatically and provided electronically to practitioners for review with their patient. The information that is obtained is incorporated by practitioners in advising next steps for blood pressure management.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female of age ≥ 18 years
  • Essential hypertension, consisting of:
  • Blood pressure ≥150 or ≥90 during chronic treatment with 2 or more drugs for patients ≥80 years of age; or,
  • Blood pressure ≥140 or≥90) during chronic treatment with 2 or more drugs for patients <80 years of age
  • Ability to read and understand the instructions for participating
  • Capacity to read and to speak English proficiently
  • Capacity to provide informed consent

Exclusion criteria

  • History of skin sensitivity to adhesive medical tape or metals
  • History of acute or chronic dermatitis
  • Any other condition that in the investigators opinion would compromise patient safety while participating
  • Alcohol or other substance abuse
  • Terminal illness

Treatment and study plan

Ingestible Sensor and Wearable Sensor

Other

This digital health offering passively acquires and records medication-taking and habits of daily living.

Primary outcomes

  1. Frequency of Medication-taking (% Taking Adherence)

    Time frame: 2 weeks

    Percent timing adherence is determined by the number of ingestion sensors detected by the wearable monitor, divided by the total number of ingestion sensors prescribed, for the 2 week-time frame.

  2. Pattern of Medication-taking (% Scheduling Adherence)

    Time frame: 2 weeks

    Percent scheduling adherence is determined by the number of ingestion sensors detected within a ± 2-hour time window around the prescribed dosing period, divided by the number of ingestion sensors detected by the wearable sensor during that dosing period, over the 2-week time frame.

Secondary outcomes

  1. Proportion of Patients Capable of Achieving Blood Pressure Control on Existing Treatment

    Time frame: 2 weeks

    Percentage of participants

  2. Change in Systolic and Diastolic Blood Pressure After Use of Digital Health Offering

    Time frame: 2 weeks

    Decrease in systolic and diastolic blood pressure (measured in mm Hg) after 2 weeks when compared to baseline

  3. Blood Pressure Management After Use of Digital Health Offering

    Time frame: 4 weeks

    Summary of provider actions following review of final report with patient (dose or medication change, adherence counseling, referral to a hypertension specialist)

Sponsors and collaborators

Lead sponsor

Proteus Digital Health, Inc.

Industry

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2015
First posted
Sep 17, 2015
Registry last updated
Jun 16, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.